Page 912 - Cardiac Nursing

0
0
6
9
/
/
2
2
009
6
/
/
88.
qx
qx
6-8
88.
88.
2
9
9
d
d
2
e 8
88
88
g
g
e 8
ar
a
a
Apt
Apt
ar
1
0:0
0:0
009
009
1
M
Pa
Pa
1 P
1 P
M
6-8
39_
0-c
0-c
p87
p87
39_
LWB
LWB
LWBK340-c39_p876-888.qxd 29/06/2009 10:01 PM Page 888 Aptara
K34
K34
K34
6-8
888 PA R T V / Health Promotion and Disease Prevention
domized prospective 6-year study. Diabetes Research and Clinical Practice, 56. International Diabetes Federation (IDF). (2005). Global guidelines for type
8
8
28, 103–117. 2 diabetes. Chapter 5: Lifestyle management. Brussels: International Diabetes
47. UK Prospective Diabetes Study Group (UKPDS). (1998). Intensive Federation.
blood-glucose control with sulphonylureas or insulin compared with con- 57. American Diabetes Association (ADA). (2008). Nutrition recommenda-
ventional treatment and risk of complications in patients with type 2 dia- tions and interventions for diabetes—2008. Diabetes Care, 31, S61–S78.
betes. The Lancet, 352, 837–853. 58. American Diabetes Association (ADA). (2004). Preventative foot care in
2
2
48. International Diabetes Federation (IDF). (2005). Global Guidelines for diabetes. Diabetes Care, 27, S63–S64.
7
7
Type 2 Diabetes Chapter 6: Glucose control levels. Brussels: International 59. Nathan, D. M., Buse, J. B., Davidson, M. B., et al. (2006). Management
Diabetes Federation. of hyperglycemia in type 2 diabetes: A consensus algorithm for the initia-
49. International Diabetes Federation (IDF). (2005). Global Guidelines for tion and adjustment of therapy: A consensus statement from the Ameri-
Type 2 Diabetes Chapter 11: Blood pressure control. Brussels: International can Diabetes Association and the European Association for the Study of
9
9
Diabetes Federation. Diabetes. Diabetes Care, 29, 1963–1972.
50. UK Prospective Diabetes Study Group (UKPDS). (1998). Tight blood 60. American Diabetes Association (ADA). (2007). Once-weekly exenatide
pressure control and risk of macrovascular and microvascular complica- safe and effective. DOC News, 4(7). Retrieved January 16th, 2008, from
tions in type 2 diabetes. BMJ, 317, 703–713. http://docnews.diabetesjournals.org/cgi/content/full/4/7/18-a?
51. Hansson, L., Zanchetti, A., Carruthers, S. G., et al. (1998). Effects of in- ck nck
tensive blood-pressure lowering and low-dose aspirin in patients with hy- 61. Misbin, R. I. (2004). The phantom of lactic acidosis due to metformin in
7
pertension: Principal results of the Hypertension Optimal Treatment patients with diabetes. Diabetes Care, 27, 1791–1793.
7
(HOT) randomised trial. The Lancet, 351, 1755–1762. 62. Singh, S., Loke, Y. K., & Furberg, C. D. (2007). Long-term risk of
52. Heart Outcomes Prevention Evaluation Study Investigators (HOPE). cardiovascular events with rosiglitazone: A meta-analysis. JAMA, 298,
(2000). Effects of ramipril on cardiovascular and microvascular outcomes 1189–1195.
in people with diabetes mellitus: Results of the HOPE study and MICRO- 63. Nissen, S. E., & Wolski, K. (2007). Effect of rosiglitazone on the risk of
HOPE substudy. Lancet, 355, 253–259. myocardial infarction and death from cardiovascular causes. New England
53. International Diabetes Federation (IDF). (2005). Global guidelines for type Journal of Medicine, 356, 2457–2471.
6
6
2 diabetes. Chapter 12: Cardiovascular risk protection. Brussels: International 64. Mooradian, A. D., Bernbaum, M., Albert, S. G., et al. (2006). Narrative
Diabetes Federation. review: A rational approach to starting insulin therapy. Annals of Internal
54. American Diabetes Association (ADA). (2004). Smoking and diabetes. Medicine, 145, 125–134.
Diabetes Care, 27, S74–S75. 65. Rosenstock, J., Dailey, G., Massi-Benedetti, M., et al. (2005). Reduced
7
7
55. Collins, R., Armitage, J., Parish, S., & Heart Protection Study Collabora- hypoglycemia risk with insulin glargine: A meta-analysis comparing in-
tive Group. (2004). Effects of cholesterol-lowering with simvastatin on sulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care,
8
8
stroke and other major vascular events in 20536 people with cerebrovas- 28, 950–955.
cular disease or other high-risk conditions. The Lancet, 363, 757–767.